Description
Contact hours available until 10/31/2017.
Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation.
Nephrology Nursing Journal Editorial Board Statements of Disclosure
In accordance with ANCC governing rules Nephrology Nursing Journal Editorial Board statements of disclosure are published with each CNE offering. The statements of disclosure for this offering are published below.
Paula Dutka MSN, RN, CNN, disclosed that she is a coordinator of Clinical Trials for the following sponsors: Amgen, Rockwell Medical, Keryx Biopharmaceuticals, Akebia Therapeutics, and Dynavax Technologies.
Norma J. Gomez, MBA, MSN, CNNe, disclosed that she is a member of the ZS Pharma Advisory Council.
Carol M. Headley DNSc, ACNP-BC, RN, CNN, disclosed that she is a Consultant and/or member of the Corporate Speaker’s Bureau for Sanofi Renal, and a member of the Advisory Board for Amgen.
Tamara M. Kear, PhD, RN, CNS, CNN, disclosed that she is a Fresenius employee, and freelance editor for Lippincott, Williams & Wilkins and Elsevier publishing companies.
All other members of the Editorial Board had no actual or potential conflict of interest in relation to this continuing nursing education activity.
This article was reviewed and formatted for contact hour credit by Beth Ulrich, EdD, RN, FACHE, FAAN, Nephrology Nursing Journal Editor, and Sally Russell, MN, CMSRN, CPP ANNA Education Director.
There are no other disclosures to declare.
This article was reviewed and formatted for contact hour credit by Beth Ulrich, EdD, RN, FACHE, FAAN, Nephrology Nursing Journal Editor, and Sally Russell, MN, CMSRN, CPP ANNA Education Director.
Commercial Support and Sponsorship:
No commercial support or sponsorship declared.
Accreditation Statement:
American Nephrology Nurses’ Association is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Goal
To provide an overview of the physiological importance of rapid blood pressure decrease during hemodialysis, and the pathological consequences of repeated asymptomatic and symptomatic hypoperfusive episodes.
Objectives:
- Define intradialytic hypotension (IDH).
- Discuss the challenges IDH poses to patients and nephrology clinicians in hemodialysis settings.
- Describe the use of an algorithmic intervention pathway that considers mean arterial pressure (MAP) as the blood pressure metric to reduce IDH in patients on hemodialysis.
